Research programme: immuno-oncology targeted antibodies - Checkpoint Therapeutics

Drug Profile

Research programme: immuno-oncology targeted antibodies - Checkpoint Therapeutics

Alternative Names: Anti-CAIX antibodies; Anti-GITR antibodies; Anti-PD-L1 antibodies; CK 301; CK 302

Latest Information Update: 14 Mar 2016

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Checkpoint Therapeutics; TG Therapeutics Inc
  • Class Antibodies
  • Mechanism of Action Carbonic anhydrase inhibitors; CD274 antigen inhibitors; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 14 Mar 2016 Preclinical trials in Renal cell carcinoma in USA (unspecified route) before March 2016
  • 21 Dec 2015 Checkpoint Therapeutics plans an IND application in Cancer for its Immunooncology targeted antibodies
  • 04 Mar 2015 Anti-PD-L1 and Anti-GITR antibodies sub-licensed to TG Therapeutics worldwide for the treatment of Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top